Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen
Erschienen in:

17.03.2021 | Originalien

Pleiotrope Wirkung von Vitamin D mit Berücksichtigung von COVID-19

verfasst von: PD Dr. med. habil. Stephan H. Scharla

Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Vitamin D wird aus der Nahrung aufgenommen oder in der Haut unter Einwirkung von UV-Licht gebildet. In der Leber wird 25(OH)-Vitamin D gebildet und in der Niere 1,25(OH)2-Vitamin D, welches als Hormon den Knochen- und Mineralstoffwechsel reguliert.
Außerhalb der Niere besitzen viele Organe Enzyme, um 1,25(OH)2-Vitamin D zu bilden für autokrine und parakrine Wirkungen. Für diese pleiotropen Effekte erscheint eine gleichmäßige Vitamin-D-Versorgung (tägliche Vitamin-D-Supplementation) mit mäßiger Dosierung besser wirksam als hoch dosierte Bolusapplikationen. Neben der klassischen Wirkung von 1,25(OH)2-Vitamin D auf das muskuloskelettale System sind unter den extraskelettalen Wirkungen insbesondere die immunregulatorischen Effekte mittlerweile sehr gut belegt. So kann durch eine gute Vitamin-D-Versorgung das Risiko für respiratorische Infekte vermindert werden, was gerade im Hinblick auf die aktuelle COVID-19(Coronavirus-Erkrankung-19)-Pandemie von Bedeutung erscheint.
Vorheriger Artikel Editorial
Nächster Artikel Genetische Analysen bei hereditären Bindegewebserkrankungen
Literatur
1.
Barger-Lux MJ, Heaney RP, Lanspa SJ, Healy JC, DeLuca HF (1995) An investigation of sources of variation in calcium absorption efficiency. J Clin Endocrinol Metab 80:406–411PubMed
2.
Hollis BW, Wagner CL (2013) The role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab 98:4619–4628PubMedPubMedCentralCrossRef
3.
Nykjaer A, Dragun D, Walther D et al (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96:507–515PubMedCrossRef
4.
Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh J, Jurutka PW (2013) Molecular mechanisms of vitamin D action. Calcif Tissue Int 92:77–98PubMedCrossRef
5.
Scharla SH, Strong DD, Rosen C, Mohan S, Holick M, Baylink DJ, Linkhart TA (1993) 1,25-dihydroxyvitamin D3 increases secretion of insulin-like growth factor binding protein‑4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP‑4 serum levels in vivo. J Clin Endocrinol Metab 77:1190–1197PubMed
6.
Scharla S (2016) Einfluss von Vitamin D auf Knochen und Muskel. Diabetologe 12:261–268CrossRef
7.
Infante M, Ricordi C, Sanchez J, Clare-Salzler MJ, Padilla N, Fuenmayor V, Chavez C, Alvarez A, Baidal D, Alejandro R, Caprio M, Fabbri A (2019) Influence of vitamin D on islet autoimmunity and beta-cell function in type 1 diabetes. Nutrients 11:2185. https://​doi.​org/​10.​3390/​nu11092185CrossRefPubMedCentral
8.
Mathieu C (2011) Vitamin D and the immune system: getting it right. IBMS Bonekey 8:178–186CrossRef
9.
Colin EM, Asmawidjaja PS, van Hamburg JP, Mus AM, van Driel M, Hazes JM, van Leeuwen JP, Lubberts E (2010) 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 62:132–142PubMedCrossRef
10.
Scharla S (2008) Diagnosis of disorders of vitamin D‑metabolism and osteomalacia. Clin Lab 54:451–459PubMed
11.
Scharla S (2019) Osteomalazie. In: Lehnert H (Hrsg) DGIM Innere Medizin. Springer, Berlin, Heidelberg
12.
Scharla SH, Scheidt-Nave C, Leidig G, Woitge H, Wüster C, Seibel MJ, Ziegler R (1996) Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females. A population-based study. Exp Clin Endocrinol Diabetes 104:289–292PubMedCrossRef
13.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676PubMedCrossRef
14.
Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H (2009) Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int 20:315–322PubMedCrossRef
15.
Chapuy MC, Arlot ME, Duboeuf F et al (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642PubMedCrossRef
16.
Bolland MJ, Grey A, Avenell A (2018) Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol 6:847–858PubMedCrossRef
17.
Appel LJ, Michos E, Mitchell CM, Blackford AL, Sternberg AL, Miller ER, Juraschek SP, Schrack JA, Szanton SL, Charleston J, Minotti M, Baksh SN, Christenson RH, Coresh J, Drye LT, Guralnik JM, Kalyani RR, Plante TB, Shade DM, Roth DL, Tonascia J (2021) The effects of four doses of vitamin D supplements on falls in older adults: a response-adaptive, randomized clinical trial. Ann Intern Med 174:145–156PubMedCrossRef
18.
Sanders KM, Stuart AL, Williamson EJ et al (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303:1815–1822PubMedCrossRef
19.
20.
Ginde AA, Blatchford P, Breese K, Zarrabi L, Linnebur SA, Wallace JI, Schwartz RS (2017) High dose monthly vitamin D for prevention of acute respiratory infection in older long-term care residents: a randomized clinical trial. J Am Geriatr Soc 65:496–503PubMedCrossRef
21.
Zheng YT, Cui QQ, Hong YM, Yao WG (2015) A meta-analysis of high dose, intermittent vitamin D supplementation among older adults. PLoS ONE 10:e115850PubMedPubMedCentralCrossRef
22.
23.
Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92:1415–1423PubMedCrossRef
24.
Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala N‑B, Clarke A, Franco OH (2010) Levels of vitamin D and cardiometabolic disorders: Systematic review and meta-analysis. Maturitas 65:225–236PubMedCrossRef
25.
Pilz S, März W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, Boehm BO, Dobnig H (2008) Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary Angiography. J Clin Endocrinol Metab 93:3927–3935PubMedCrossRef
26.
Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, Grant AM, Campbell MK, Anderson FH, Cooper C, Francis RM, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA, RECORD Trial Group (2012) Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trail). J Clin Endocrinol Metab 97:614–622PubMedCrossRef
27.
28.
Manson JE, Cook NR, Lee I‑M et al (2019) Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 380:33–44PubMedCrossRef
29.
Lee YH, Bae SC (2016) Vitamin D level in rheumatoid arthritis and ist correlation with the disease activity: a meta-analysis. Clin Exp Rheumatol 34:827–833PubMed
30.
31.
Scharla SH, Schacht E, Lempert UG (2005) Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J Rheumatol 32(Suppl 76):26–32
32.
Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D’Souza C, Ursell M, O’Connor P (2010) A phase 1/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 74:1852–1859PubMedPubMedCentralCrossRef
33.
34.
Smolders J, Torkildsen Ø, Camu W, Holmøy T (2019) An update on vitamin D and disease activity in multiple sclerosis. CNS Drugs 33:1187–1199PubMedPubMedCentralCrossRef
35.
Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R (1992) 1,25-dihydroxyvitamin D 3 prevents insulitis in NOD Mice. Diabetes 41:1491–1495PubMedCrossRef
36.
Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R (1994) Prevention of autoimmune diabetes in NOD mice by 1,25-dihydroxyvitamin D. Diabetologia 37:552–558PubMedCrossRef
37.
Takiishi T, Ding L, Baeke F, Spagnuolo I, Sebastiani G, Laureys J, Verstuyf A, Carmeliet G, Dotta F, Van Belle TL, Gysemans A, Mathieu C (2014) Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes incidence in NOD mice when given early and long term. Diabetes 63:2026–2036PubMedCrossRef
38.
EURODIAB ACE Study Group (2000) Variation and trends in incidence of childhood diabetes in Europe. Lancet 355:873–876CrossRef
39.
Mohr SB, Garland CF, Gorham ED, Garland FC (2008) The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 51:1391–1398PubMedCrossRef
40.
Gorham ED, Garland CF, Burgi AA, Mohr SB, Zeng K, Hofflich H (2012) Lower prediagnostic serum 25-hydroxyvitamin D concentration is associated with higher risk of insulin-requiring diabetes: a nestet case-control study. Diabetologia 55:3224–3227PubMedCrossRef
41.
Cadario F, Savastio S, Pagliardini V, Bagnati M, Vidali M, Cerutti F (2015) Vitamin D levels at birth and risk of type 1 diabetes in childhood: A case-control study. Acta Diabetol 52:1077–1081PubMedCrossRef
42.
Mäkinen M, Mykkänen J, Koskinen M, Simell V, Veijola R, Hyöty H (2016) Serum 25-Hydroxyvitamin D concentrations in children progressing to autoimmunity and clinical type 1 diabetes. J Clin Endocrinol Metab 101:723–729PubMedCrossRef
43.
Gabbay MAL, Sato MN, Finazzo C, Duarte AJS, Dib SA (2012) Effect of cholecalciferol as adjungtive therapy with insulin on protective immunologic profile and decline of residual b‑cell function in new-onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med 166:601–607PubMedCrossRef
44.
Treiber G, Prietl B, Fröhlich-Reiterer E, Lechner E, Ribitsch A, Fritsch M, Rami-Merhar B, Steigleder-Schweiger C, Graninger W, Borkenstein M, Pieber TR (2015) Cholecalciferol supplementation improves suppressive capacity of regulatory T‑cells in young patients with new-onset type 1 diabetes mellitus—A randomized clinical trial. Clin Immunol 161:217–224PubMedCrossRef
45.
Penna-Martinez M, Hess H, Doering C, Nejatian N, Bogdanou D, Shoghi F, Hansmann ML, Badenhoop K (2016) High dose vitamin D treatment regulates the gene expression pattern in T‑Helper cells of type 1 diabetes patients. Poster P10-05. Abstract-CD D A C H‑Tagung 2016, 59. Symposium der Deutschen Gesellschaft für Endokrinologie, 21. Jahrestagung der Österreichischen Gesellschaft für Endokrinologie und Stoffwechsel und Frühjahrstagung 2016 der Schweizerischen Gesellschaft für Endokrinologie und Diabetologie – URN: urn:nbn:de:101:1–201604282025.CrossRef
46.
Bogdanou D, Penna-Martinez M, Filmann N, Chung TL, Moran-Auth Y, Wehrle J, Cappel C, Huenecke S, Herrmann E, Koehl U, Badenhoop K (2017) T‑lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: a randomized controlled trial with sequential crossover. Diabetes Metab Res Rev. https://​doi.​org/​10.​1002/​dmrr.​2865CrossRefPubMed
47.
Mishra A, Dayal D, Sachdeva N, Attri SV (2015) Effect of 6‑months’s vitamin D supplementation on residual beta cell function in children with type 1 diabetes: a case control interventional study. J Pediatr Endocrinol Metab 29:395–400CrossRef
48.
Giri D, Pintus D, Burnside G, Ghatak A, Mehta F, Paul P, Senniappan S (2017) Treating vitamin D deficiency in children with type I diabetes could improve their glycaemic control. BMC Res Notes 10:465PubMedPubMedCentralCrossRef
49.
Panjiyar RP, Dayal D, Attri SV, Sachdeva N, Sharma R, Bhalla AK (2018) Sustained serum 25-hydroxyvitamin D concentrations for one year with cholecalciferol supplementation improves glycaemic control and slows the decline of resitual β‑cell function in children with type 1 diabetes. Pediatr Endocrinol Diabetes Metab 24:111–117CrossRef
50.
Shih EM, Mittelman S, Pitukcheewanont P, Azen CG, Monzavi R (2016) Effects of vitamin D repletion on glycemic control and inflammatory cytokines in adolescents with type 1 diabetes. Pediatr Diabetes 17:36–43PubMedCrossRef
51.
Sharma S, Biswal N, Bethou A, Rajappa M, Kumar S, Vinayagam V (2017) Does vitamin D supplementation improve glycaemic control in children with type 1 diabetes mellitus?—A randomized controlled trial. J Clin Diagnostic Res 11:SC15–SC17
52.
Perchard R, Magee L, Whatmore A, Ivison F, Murray P, Stevens A, Mughal MZ, Ehtisham S, Campbell J, Ainsworth S, Marshall M, Bone M, Doughty I, Clayton PE (2017) A pilot interventional study to evaluate the impact of cholecalciferol treatment on HBA1c in type 1 diabetes (T1D). Endocr Connect 6:225–231PubMedPubMedCentralCrossRef
53.
Pitocco D, Crinò A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, Anguissola B, Visalli N, Suraci C, Matteoli MC, Patera IP, Cavallo MG, Bizzari C, Pozzilli P, IMDIAB group (2006) The effects of calcitriol and nicotinamide on residual pancreatic β‑cell function in patients with recent onset type 1 diabetes (IMDIAB XI). Diabetic Med 23:920–923PubMedCrossRef
54.
Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG (2010) No effect of the 1a,25-dihydroxyvitamin D3 on beta cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 33:1443–1448PubMedPubMedCentralCrossRef
55.
Bizzari C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P, IMDIAB Group (2010) No protective effect of calcitriol on β‑cell function in recent-onset type 1 diabetes. Diabetes Care 33:1962–1963CrossRef
56.
Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z (2009) Protective effects of 1‑alpha-hydroxyvitamin D3 on residual beta cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 25:411–416PubMedCrossRef
57.
Ataie-Jafari A, Loke S‑C, Rahmat AB, Larijani B, Abbasi F, Leow KS, Yassin Z (2013) A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clin Nutr 32:911–917PubMedCrossRef
58.
Lempert UG, Scharla SA, Scharla SHJ (2020) Einfluss von Body-Mass-Index, 25-hydroxyvitamin D und HbA1c auf Myostatin. Osteologie 29:50
59.
Scharla SH (2020) Knochen und Diabetes mellitus. Osteologie 29:7–12CrossRef
60.
Li X, Liu Y, Zheng Y, Wang P, Zhang Y (2018) The effect of vitamin D supplementation on glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Nutrients 10:375PubMedCentralCrossRef
61.
Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, Brodsky I, Ceglia L, Chadha C, Chatterjee R, Desouza C, Dolor R, Foreyt J, Fuss P, Ghazi A, Hsia DS, Johnson KC, Kashyap SR, Kim S, LeBlanc ES, Leweis MR, Liao E, Neff LM, Nelson J, O’Neil P, Park J, Peters A, Phillips LS, Pratley R, Raskin P, Rasouli N, Robbins D, Rosen C, Vickery EM, Staten M, for the D2d Research Group (2019) Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med 381:520–530PubMedPubMedCentralCrossRef
62.
Simsek Y, Cakir I, Yetmis M, Dizdar OS, Baspinar O, Gokay F (2016) Effects of vitamin D treatment on thyroid autoimmunity. J Res Med Sci 21:85PubMedPubMedCentralCrossRef
63.
Mazokopakis EE, Papadomanolaki MG, Tsekouras KC, Evangelopoulos AD, Kotsiris DA, Tzortzinis AA (2015) Is vitamin D related to pathogenesis and treatment of Hashimotos’s thyroiditis? Hell J Nucl Med 18:222–227PubMed
64.
Chaudhary S, Dutta D, Kumar M, Saha S, Mondal SA, Kumar A, Mukhopadhyay S (2016) Vitamin D supplementation reduces thyroid peroxidase antibody levels in patients with autoimmune thyroid disease: an open-labeled randomized controlled trial. Indian J Endocrinol Metab 20:391–398PubMedPubMedCentralCrossRef
65.
Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnel SL (2017) Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA 317:1234–1243PubMedCrossRef
66.
Scharla SH (2019) Vitamin D in der Reproduktionsmedizin. Gynäkologische Endokrinologie 17:16–19CrossRef
67.
Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, Timms PM, Venton TR, Bothamley GH, Packe GE, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Meim CA, Bhaw-Rosun L, Nuamah R, Young DB, Drobniewski FA, Griffiths CJ, Martineau AR (2012) Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 109:15449–15454PubMedPubMedCentralCrossRef
68.
Bergmann P, Lindh AU, Björkhem-Bergman L, Lindh JD (2013) Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. Plos One 8:e65835CrossRef
69.
Martineau AR, Jolliffe DA, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Janssens W, Jensen ME, Kerley CP, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S, Stelmach I, Kumar GT, Uraschima M, Camargo CA, Griffiths CJ, Hooper RL (2019) Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. Health Technol Assess 23:1–44PubMedPubMedCentralCrossRef
70.
Pham H, Waterhouse M, Baxter C, Romero BD, McLeod DSA, Armstrong BK et al (2021) The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D‑Health Trial. Lancet Diabetes Endocrinol 9:69–81PubMedCrossRef
71.
Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, Islam K, McLaughlin D, Bhowmik A, Timms PM, Rajajulasingam RK, Rowe M, Venton TR, Choudhury AB, Simcock DE, Wilks M, Degun A, Sadique Z, Monteiro WR, Corrigan CJ, Hawrylowicz CM, Griffiths CJ (2015) Vitamin D supplementation in patients with chronic obstructive pulmonary disease (ViDiCo): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 3:120–130. https://​doi.​org/​10.​1016/​S2213-2600(14)70255-3CrossRefPubMed
72.
Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H (2010) Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 91:1255–1260PubMedCrossRef
73.
74.
Xu Yi, Baylink DJ, Chen CS, Reeves ME, Xiao J, Lacy C, Lau E, Cao H (2020) The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19. J Transl Med 18:322PubMedPubMedCentralCrossRef
75.
76.
Merzon E, Tworowski D, Gorohovski A, Vinker S, Cohen AG, Green I, Frenkel-Morgenstern (2020) Low plasma 25(OH)vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J 287:3693–3702PubMedCrossRef
77.
Hernandez JL, Nan D, Fernandez-Ayala M, Garcia-Unzueta M, Hernandez-Hernandez MA, Lopez-Hoyos M, Munoz-Ccho P, Omos JM, Gutierrez-Cuadra M, Ruiz-Cubillan JJ, Crespo J, Marinez-Taboada VM (2020) Vitamin D status in hospitalized patients with SARS-coV‑2 infection. J Clin Endocrinol Metab. https://​doi.​org/​10.​1210/​clinem/​dgaa733CrossRef
78.
Hutchings N, Babalyan V, Baghdasaryan S, Qefoyan M, Sargsyants N, Aghajanova E, Martirosyan A, Harutyunyan R, Lesnyak O, Formenti AM, Giustina A, Bilezikian JP (2021) Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. Endocrine 16:1–3. https://​doi.​org/​10.​1007/​s12020-020-02597-7CrossRef
79.
Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, Boot CS, Stock N, Macfarlane J, Martineau AR, Burns G, Quinton R (2020) Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. Clin Endocrinol 93:508–511CrossRef
80.
Vassiliou AG, Jahaj E, Pratikaki M, Orfanos SE, Dimopoulou I, Kotanidou A (2020) Low 25-Hydroxyvitamin D levels on admission to the intensive care unit may predispose COVID-19 pneumonia patients to a higher 28-day mortality risk: a pilot study on a greek ICU cohort. Nutrients 12:3773PubMedCentralCrossRef
81.
Karahan S, Katkat F (2021) Impact of serum 25(OH)Vitamin D level on mortality in patients with COVID-19 in Turkey. J Nutr Health Aging 25:189–196PubMedCrossRef
82.
83.
Orchard L, Baldry M, Nasim-Mohi M, Monck C, Saeed K, Grocott MPW, Ahilanandan D, University Hospital Southampton Critical Care Team and the REACT COVID Investigators (2021) Vitamin D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients. Clin Chem Lab Med. https://​doi.​org/​10.​1515/​cclm-2020-1567CrossRefPubMed
84.
Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz C, Jani BD, Welsh P, Mair FS, Gray SR, O’Donnell CA, Gill JMR, Sattar N, Pell JP (2020) Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr 14:561–565PubMedPubMedCentralCrossRef
85.
86.
Ohaegbulam KC, Swalih M, Patel P, Smith MA, Perrin R (2020) Vitamin D supplementation in COVID-19 patients: a clinical case series. Am J Ther 27:e485–e490PubMedCrossRef
87.
88.
Annweiler C, Hanotte B, de lÉprevier C, Sabatier JM, Lafaie L, Célarier T (2020) Vitamin D and survival in COVID-19 patients: a quasi-experimental study. J Steroid Biochem Mol Biol 204:105771PubMedPubMedCentralCrossRef
89.
Castillo ME, Costa LME, Barrios JMV, Diaz JFA, Miranda JL, Bouillon R, Gomez JMQ (2020) Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol 203:105751CrossRef
90.
91.
92.
Metadaten
Titel
Pleiotrope Wirkung von Vitamin D mit Berücksichtigung von COVID-19
verfasst von
PD Dr. med. habil. Stephan H. Scharla
Publikationsdatum
17.03.2021
Verlag
Springer Vienna
Erschienen in
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen / Ausgabe 1/2021
Print ISSN: 2412-8260
Elektronische ISSN: 2412-8287
DOI
https://doi.org/10.1007/s41970-021-00146-w

Weitere Artikel der Ausgabe 1/2021

News-Screen Orthopädie & Traumatologie

  • News-Screen Orthopädie & Traumatologie

Sturz, Sarkopenie und Osteoporose

  • Originalien

News-Screen Rheumatologie

  • News-Screen Rheumatologie

Mitteilungen der ÖGKM

  • Mitteilungen der ÖGKM

Editorial

  • Editorial

Mitteilungen des Magnesiumforum Bad Radkersburg

  • Mitteilungen des Magnesiumforum Bad Radkersburg